190 related articles for article (PubMed ID: 31200362)
1. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
2. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.
Chen XS; Wu JY; Huang O; Chen CM; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Oncol Rep; 2010 May; 23(5):1213-20. PubMed ID: 20372832
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
8. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
10. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Vaz-Luis I; Ottesen RA; Hughes ME; Mamet R; Burstein HJ; Edge SB; Gonzalez-Angulo AM; Moy B; Rugo HS; Theriault RL; Weeks JC; Winer EP; Lin NU
J Clin Oncol; 2014 Jul; 32(20):2142-50. PubMed ID: 24888816
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
12. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
13. Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients.
Ebner F; van Ewijk R; Wöckel A; Hancke K; Schwentner L; Fink V; Kreienberg R; Janni W; Blettner M
Breast; 2015 Jun; 24(3):256-62. PubMed ID: 25769974
[TBL] [Abstract][Full Text] [Related]
14. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
[TBL] [Abstract][Full Text] [Related]
15. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
16. Surgical Management of Breast Cancer in 2010-2011 SEER Registries by Hormone and HER2 Receptor Status.
Lizarraga I; Schroeder MC; Weigel RJ; Thomas A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S566-72. PubMed ID: 25956579
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
20. Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction.
Wu W; Cheng S; Deng H; Wu J; Mao K; Cao M
Medicine (Baltimore); 2016 Jan; 95(3):e2547. PubMed ID: 26817902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]